U.S. Antitrust Investigation of Generics to Look into Two Dozen Drugs - Bloomberg
- World stocks hold near 16-month highs after strong week
- Broadcom Ltd. (AVGO) Tops Q4 EPS by 11c
- Oil edges higher on optimism over non-OPEC output cuts
- Restoration Hardware (RH) Tops Q3 EPS by 4c; Guides Well Below the Street
- Sibanye Gold (SBGL) to Acquire Stillwater Mining Company (SWC) in $2.2B Deal
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - November 3, 2016 2:23 PM EDT)
U.S. prosecutors are "bearing down" on generic pharma companies in a sweeping criminal investigation into suspected price collusion, according to Bloomberg. The antitrust investigation by the DOJ spans more than a dozen companies and two dozen drugs, sources told the news service. A grand jury probe is examining some executives and the first charges could emerge by the end of the year.
Companies mentioned in the report include Mylan (NASDAQ: MYL), Allergan (NYSE: AGN) and Teva Pharma (NYSE: TEVA), Lannett (NYSE: LCI), Impax Laboratories (NASDAQ: IPXL), Covis, Sun Pharma, Mayne, Endo (NASDAQ: ENDP), and Taro Pharma (NYSE: TARO).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Beijing to Slash Amount Withdrawn from ATMs in Macau to Reduce Currency Flight -SCMP (MGM) (LVS) (WYNN) (MPEL)
- Venaxis (APPY) Changes Name to Bioptix; Will Trade Under Ticker 'BIOP'
- UPDATE: Macy's (M), Sears (SHLD), Kohl's Corp. (KSS) Accused of Posting Fake 'Original' Prices - Bloomberg
Create E-mail Alert Related CategoriesCorporate News, ETFs, Hot Corp. News, Litigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!